AIM ImmunoTech Inc. — Director's Dealing 2019

Jun 17, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: HEMISPHERX BIOPHARMA INC (HEB)
CIK: 0000946644
Period of Report: 2019-03-18

Reporting Person: EQUELS THOMAS K. (Director, Exec. Vice Chairman/CEO/Pres.)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-03-18	Common Stock	C	325000	—	Acquired	1136707	Direct
2019-05-08	Common Stock	C	227500	—	Acquired	1364207	Direct

Footnotes

F1: Each share has a stated value of $1,000 and was converted into 5,000 shares of Series B Common Stock for each of the 65 shares issued.

F2: Rights offering warrants using the cashless conversion feature , were converted into .70 number of shares.